ONCBeOne MedicinesSigning up patients
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
Advanced Esophageal Squamous Cell Carcinoma · Metastatic Esophageal Squamous Cell Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 30 (planned)
- Started
- Sep 14, 2026
- Main results expected
- Feb 28, 2028
- Fully finished
- Feb 28, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Serum Concentrations of Tislelizumab at Specified Time Points
Measured over: Approximately 12 months
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: Approximately 12 months
Overall Response Rate (ORR)Assessed by Independent Review Committee (IRC)
Measured over: Approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07733180 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC